Fitch affirms Arch Pharmalabs program

Fitch Ratings said it affirmed Arch Pharmalabs Ltd.'s Rs. 1 billion commercial paper/short-term debt program at F1(ind).

The rating continues to reflect the company's strong business growth in FY10 with revenues increasing by 19% as a result of its established active pharmaceutical ingredient portfolio and a positive growth in its recent contract manufacturing and co-marketing activities, the agency noted.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.